AMS and Tracer Studies at GSK – A ripple or a wavefront?
Graeme Young – GSK: AMS – a ripple or a wavefront?
Microdosing studies: a consideration on analytical technology choice
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.